The estimated Net Worth of Barclay A Phillips is at least $7.66 Million dollars as of 15 November 2018. Mr. Phillips owns over 5,000 units of Immunic stock worth over $7,600 and over the last 19 years he sold IMUX stock worth over $7,494,747. In addition, he makes $158,788 as Independent Director at Immunic.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Phillips IMUX stock SEC Form 4 insiders trading
Barclay has made over 16 trades of the Immunic stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of IMUX stock worth $97,300 on 15 November 2018.
The largest trade he's ever made was selling 235,000 units of Immunic stock on 13 June 2008 worth over $7,120,500. On average, Barclay trades about 11,709 units every 115 days since 2006. As of 15 November 2018 he still owns at least 5,000 units of Immunic stock.
You can see the complete history of Mr. Phillips stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barclay Phillips biography
Barclay (Buck) A. Phillips serves as Independent Director of the Company., with effective 14 November 2019. Until recently, Mr. Phillips was Chief Financial Officer and Senior Vice President of Corporate Development at G1 Therapeutics, Inc., where, among other achievements, he was instrumental in raising over USD 300 million in multiple equity financings. Before that, he served as Senior Vice President, Chief Financial Officer and Treasurer of vaccine company, Novavax, Inc., where he helped to raise more than USD 850 million in various financings to support the company's late-stage clinical programs. Prior, Mr. Phillips was Senior Vice President and Chief Financial Officer of Micromet, Inc., which, during his tenure, was acquired by Amgen Inc. for approximately USD 1.2 billion . Mr. Phillips's exposure to venture capital came earlier, while serving as a Managing Director at Vector Fund Management, focused on investments in late-stage life sciences companies, and during his time as Biotechnology Analyst and Director of Venture Investments at Invesco, where he held primary coverage responsibility for the universe of publicly traded biotechnology companies, while managing the firm's private equity investing, with a focus on life sciences.
What is the salary of Barclay Phillips?
As the Independent Director of Immunic, the total compensation of Barclay Phillips at Immunic is $158,788. There are 11 executives at Immunic getting paid more, with Daniel Vitt having the highest compensation of $2,383,930.
How old is Barclay Phillips?
Barclay Phillips is 58, he's been the Independent Director of Immunic since 2019. There are 1 older and 14 younger executives at Immunic. The oldest executive at Immunic, Inc. is Tamar Howson, 72, who is the Independent Director.
What's Barclay Phillips's mailing address?
Barclay's mailing address filed with the SEC is 1200 AVENUE OF THE AMERICAS, SUITE 200, , NEW YORK, NY, 10036.
Insiders trading at Immunic
Over the last 5 years, insiders at Immunic have traded over $174,861 worth of Immunic stock and bought 176,506 units worth $558,583 . The most active insiders traders include Barclay A Phillips, Joerg Neermann, and Duane Nash. On average, Immunic executives and independent directors trade stock every 74 days with the average trade being worth of $15,244. The most recent stock trade was executed by Daniel Vitt on 26 February 2024, trading 14,000 units of IMUX stock currently worth $18,340.
What does Immunic do?
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
What does Immunic's logo look like?
Complete history of Mr. Phillips stock trades at Acorda Therapeutics Inc, G1 Therapeutics Inc, Novavax, and Immunic
Immunic executives and stock owners
Immunic executives and other stock owners filed with the SEC include:
-
Daniel Vitt,
President, Chief Executive Officer, Director -
Andreas Muehler,
Chief Medical Officer -
Manfred Groppel,
Chief Operating Officer -
Dr. Daniel Vitt,
CEO, Pres & Director -
Dr. Andreas Muehler Ph.D., M.D.,
Chief Medical Officer -
Glenn Whaley,
VP of Fin. and Principal Financial & Accounting Officer -
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A,
Exec. Chairman -
Jan Van den Bossche,
Independent Director -
Jorg Neermann,
Independent Director -
Vincent Ossipow,
Independent Director -
Tamar Howson,
Independent Director -
Barclay Phillips,
Independent Director -
Jessica Breu,
IR Contact Officer -
Hella Kohlhof,
Chief Scientific Officer -
Glenn Whaley,
Vice President Finance, Principal Financial and Accounting Officer -
Patrick Walsh,
Chief Bus. Officer -
Inderpal Singh,
Gen. Counsel -
Dr. Hella Kohlhof,
Chief Scientific Officer -
Dr. Manfred Gröppel,
Co-Founder & COO -
Jason Tardio,
President and COO -
Richard Alan Rudick,
Director -
Sanjay S Patel,
Chief Financial Officer -
Joerg Neermann,
Director -
Manfred Groeppel,
Chief Operating Officer -
Duane Nash,
Executive Chairman -
Monika Maria Toernsen,
Director -
Simona Skerjanec,
Director